Ionis Pharmaceuticals, Inc.
904 articles with Ionis Pharmaceuticals, Inc.
-
In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.
-
Ionis to present at RBC Capital Markets Global Healthcare Conference
5/12/2022
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022.
-
Ionis reports first quarter financial results and recent business achievements
5/4/2022
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements.
-
Ionis to host 2022 virtual Annual Meeting of Stockholders
5/2/2022
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022.
-
Ionis to hold first quarter 2022 financial results webcast
4/20/2022
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 4th at 11:30 a.m. Eastern Time to discuss its first quarter financial results and report on pipeline and business progress.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
4/4/2022
Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, and its partner, AstraZeneca, announced positive data from the ETESIAN Phase 2b study of ION449, an investigational antisense medicine designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting proprotein convertase subtilisin/kexin type 9.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Biogen and Ionis Pharmaceuticals announced that their Phase I study of BIIB078 (IONIS-C9Rx) intended for ALS did not meet clinical endpoints, so they will discontinue the program.
-
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
3/28/2022
Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people with C9orf72-associated amyotrophic lateral sclerosis (ALS).
-
Ionis to present at upcoming investor conferences - Mar 21, 2022
3/21/2022
Ionis Pharmaceuticals, Inc. announced that management will present at the following investor conferences.
-
Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?
-
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
3/16/2022
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced the publication of positive Phase 2 data for donidalorsen in the New England Journal of Medicine available at NEJM.org.
-
Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
3/7/2022
Ionis Pharmaceuticals, Inc. announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program, which honors Janice Wiesman, M.D., a leading global expert on the neurological impact of amyloidosis.
-
Ionis to present at the Cowen Annual Health Care Conference
3/1/2022
Ionis Pharmaceuticals, Inc. announced that management will participate in a panel discussion on orphan neurological disease therapeutics at the virtual Cowen 42nd Annual Health Care Conference at 9:10 a.m. ET on Monday, March 7, 2022.
-
Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
2/24/2022
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent business achievements.
-
Ionis to hold full year 2021 financial results webcast
2/10/2022
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Thursday, February 24th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2021 financial results as well as report on pipeline and business progress.
-
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
1/31/2022
Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).
-
The decision came after the Phase IIb study results demonstrating a statistically significant decrease in non-HDL-C and statistically significant reductions in triglycerides and ANGPTL3.
-
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
1/24/2022
Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition.